Acura Pharmaceuticals Company Profile (NASDAQ:ACUR)

About Acura Pharmaceuticals (NASDAQ:ACUR)

Acura Pharmaceuticals logoAcura Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products. The Company's Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is an approved and immediate-release (IR) oxycodone product in the United States. The Company's Impede technology products include Nexafed and Nexafed Sinus Pressure + Pain. Its third deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested. The Company's Aversion and Limitx technologies are intended to address methods associated with opioid and its Impede technology is directed at the extraction and conversion of pseudoephedrine into methamphetamine.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Delivery
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:ACUR
  • CUSIP: 00509L70
  • Web: www.acurapharm.com
Average Prices:
  • 50 Day Moving Avg: $0.53
  • 200 Day Moving Avg: $0.69
  • 52 Week Range: $0.40 - $3.28
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 1.35
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $4.46 million
  • Price / Sales: N/A
  • Book Value: $0.10 per share
  • Price / Book: 5.00
Profitability:
  • EBIDTA: ($6,210,000.00)
  • Net Margins: -291.24%
  • Return on Equity: -285.16%
  • Return on Assets: -79.77%
Debt:
  • Debt-to-Equity Ratio: -7.29%
  • Current Ratio: 1.25%
  • Quick Ratio: 1.15%
Misc:
  • Average Volume: 32,194 shs.
  • Beta: 2.12
  • Short Ratio: 0.73
 

Frequently Asked Questions for Acura Pharmaceuticals (NASDAQ:ACUR)

What is Acura Pharmaceuticals' stock symbol?

Acura Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACUR."

How were Acura Pharmaceuticals' earnings last quarter?

Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) posted its quarterly earnings results on Friday, May, 12th. The company reported $0.03 earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.11) by $0.14. The firm earned $2.72 million during the quarter, compared to the consensus estimate of $0.34 million. Acura Pharmaceuticals had a negative return on equity of 285.16% and a negative net margin of 291.24%. View Acura Pharmaceuticals' Earnings History.

Where is Acura Pharmaceuticals' stock going? Where will Acura Pharmaceuticals' stock price be in 2017?

2 brokerages have issued 12 month target prices for Acura Pharmaceuticals' shares. Their forecasts range from $6.00 to $10.00. On average, they anticipate Acura Pharmaceuticals' share price to reach $8.00 in the next twelve months. View Analyst Ratings for Acura Pharmaceuticals.

Who are some of Acura Pharmaceuticals' key competitors?

How do I buy Acura Pharmaceuticals stock?

Shares of Acura Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Acura Pharmaceuticals stock cost?

One share of Acura Pharmaceuticals stock can currently be purchased for approximately $0.50.

Analyst Ratings

Consensus Ratings for Acura Pharmaceuticals (NASDAQ:ACUR) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $8.00 (1,500.00% upside)

Analysts' Ratings History for Acura Pharmaceuticals (NASDAQ:ACUR)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/21/2016FBR & CoReiterated RatingOutperform$10.00N/AView Rating Details
10/18/2016Roth CapitalSet Price TargetBuy$6.00N/AView Rating Details
7/2/2015MLV & Co.Initiated CoverageBuy$2.00N/AView Rating Details
(Data available from 5/28/2015 forward)

Earnings

Earnings History for Acura Pharmaceuticals (NASDAQ:ACUR)
Earnings by Quarter for Acura Pharmaceuticals (NASDAQ:ACUR)
Earnings History by Quarter for Acura Pharmaceuticals (NASDAQ:ACUR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/12/2017Q1 2017($0.11)$0.03$0.34 million$2.72 millionViewN/AView Earnings Details
11/14/2016Q3($0.27)($0.19)$0.23 million$0.22 millionViewN/AView Earnings Details
8/8/2016Q2($0.28)($0.28)$0.19 million$0.26 millionViewN/AView Earnings Details
5/2/2016Q116($0.26)($0.28)$0.15 million$0.22 millionViewN/AView Earnings Details
2/29/2016Q315($0.03)($0.08)$2.70 million$2.68 millionViewListenView Earnings Details
8/3/2015Q215($0.02)($0.05)$2.90 million$0.34 millionViewN/AView Earnings Details
5/4/2015Q115$0.07$0.03$7.60 million$5.40 millionViewN/AView Earnings Details
3/2/2015Q414($0.09)($0.06)$0.05 million$0.53 millionViewN/AView Earnings Details
11/3/2014Q3 2014($0.08)($0.06)$0.05 million$0.15 millionViewN/AView Earnings Details
3/3/2014Q4 13($0.06)($0.29)ViewN/AView Earnings Details
8/1/2013Q2 2013($0.07)ViewN/AView Earnings Details
3/4/2013Q4 2012($0.86)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Acura Pharmaceuticals (NASDAQ:ACUR)
Current Year EPS Consensus Estimate: $-0.46 EPS
Next Year EPS Consensus Estimate: $0.37 EPS

Dividends

Dividend History for Acura Pharmaceuticals (NASDAQ:ACUR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Acura Pharmaceuticals (NASDAQ:ACUR)
Insider Ownership Percentage: 7.40%
Institutional Ownership Percentage: 31.23%
Insider Trades by Quarter for Acura Pharmaceuticals (NASDAQ:ACUR)
Institutional Ownership by Quarter for Acura Pharmaceuticals (NASDAQ:ACUR)
Insider Trades by Quarter for Acura Pharmaceuticals (NASDAQ:ACUR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/17/2015Claudius LlcMajor ShareholderSell104,823$1.08$113,208.84View SEC Filing  
1/12/2015Claudius LlcMajor ShareholderSell171,000$0.62$106,020.00View SEC Filing  
5/22/2014William G SkellyDirectorSell4,600$1.23$5,658.00View SEC Filing  
5/20/2014William G SkellyDirectorSell5,000$1.21$6,050.00View SEC Filing  
5/19/2014Albert W BrzeczkoVPBuy2,000$1.20$2,400.00View SEC Filing  
5/16/2014Bruce F WessonDirectorBuy80,000$1.13$90,400.00View SEC Filing  
5/16/2014James F EmighVPBuy15,000$1.21$18,150.00View SEC Filing  
5/16/2014Peter A ClemensCFOBuy3,000$1.21$3,630.00View SEC Filing  
5/14/2014William G SkellyDirectorSell2,900$1.21$3,509.00View SEC Filing  
5/12/2014William G SkellyDirectorSell5,000$1.25$6,250.00View SEC Filing  
5/8/2014William G SkellyDirectorSell2,500$1.30$3,250.00View SEC Filing  
3/3/2014Claudius LlcMajor ShareholderSell2,500$2.00$5,000.00View SEC Filing  
2/28/2014Claudius LlcMajor ShareholderSell351,260$2.02$709,545.20View SEC Filing  
2/24/2014Claudius LlcMajor ShareholderSell44,019$1.97$86,717.43View SEC Filing  
11/25/2013Albert W BrzeczkoVPBuy1,215$1.70$2,065.50View SEC Filing  
10/10/2013Claudius LlcMajor ShareholderSell4,200$2.05$8,610.00View SEC Filing  
8/27/2013William G SkellyDirectorSell2,000$1.55$3,100.00View SEC Filing  
7/15/2013Care Capital Ii LlcMajor ShareholderSell31,610$2.04$64,484.40View SEC Filing  
7/3/2013Care Capital Ii LlcMajor ShareholderSell14,200$2.00$28,400.00View SEC Filing  
7/2/2013Claudius LlcMajor ShareholderSell200,000$2.15$430,000.00View SEC Filing  
6/27/2013Care Capital Ii LlcMajor ShareholderSell76,281$2.01$153,324.81View SEC Filing  
6/24/2013Care Capital Ii LlcMajor ShareholderSell83,000$2.03$168,490.00View SEC Filing  
6/19/2013Care Capital Ii LlcMajor ShareholderSell114,000$2.12$241,680.00View SEC Filing  
6/17/2013Claudius LlcMajor ShareholderSell20,446$2.15$43,958.90View SEC Filing  
6/14/2013Care Capital Ii LlcMajor ShareholderSell90,000$2.16$194,400.00View SEC Filing  
6/11/2013Care Capital Ii LlcMajor ShareholderSell102,000$2.19$223,380.00View SEC Filing  
6/10/2013Claudius LlcMajor ShareholderSell21,496$2.20$47,291.20View SEC Filing  
6/6/2013Claudius LlcMajor ShareholderSell39,453$2.19$86,402.07View SEC Filing  
6/3/2013Care Capital Ii LlcMajor ShareholderSell148,000$2.24$331,520.00View SEC Filing  
5/31/2013Claudius LlcMajor ShareholderSell31,559$2.25$71,007.75View SEC Filing  
5/29/2013Care Capital Ii LlcMajor ShareholderSell108,701$2.33$253,273.33View SEC Filing  
5/28/2013William G SkellyDirectorSell2,000$2.40$4,800.00View SEC Filing  
5/23/2013Care Capital Ii LlcMajor ShareholderSell252,000$2.31$582,120.00View SEC Filing  
5/22/2013William G SkellyDirectorSell4,000$2.33$9,320.00View SEC Filing  
5/21/2013Claudius LlcMajor ShareholderSell47,410$2.30$109,043.00View SEC Filing  
5/20/2013Care Capital Ii LlcMajor ShareholderSell510,000$2.36$1,203,600.00View SEC Filing  
5/16/2013Care Capital Ii LlcMajor ShareholderSell662,000$2.38$1,575,560.00View SEC Filing  
5/16/2013William G SkellyDirectorSell3,000$2.25$6,750.00View SEC Filing  
5/15/2013Claudius LlcMajor ShareholderSell183,434$2.33$427,401.22View SEC Filing  
5/13/2013Care Capital Ii LlcMajor ShareholderSell259,000$2.19$567,210.00View SEC Filing  
5/9/2013William G SkellyDirectorSell3,000$2.20$6,600.00View SEC Filing  
4/11/2013Claudius LlcMajor ShareholderSell121,454$2.23$270,842.42View SEC Filing  
3/26/2013Care Capital Ii LlcMajor ShareholderSell39,554$2.17$85,832.18View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Acura Pharmaceuticals (NASDAQ:ACUR)
Latest Headlines for Acura Pharmaceuticals (NASDAQ:ACUR)
Source:
DateHeadline
finance.yahoo.com logoAcura Pharmaceuticals, Inc. :ACUR-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017
finance.yahoo.com - May 24 at 3:18 PM
streetinsider.com logoAcura Pharma (ACUR) Reports Initiation of Second Clinical Study on LTX-04
www.streetinsider.com - May 19 at 3:20 PM
finance.yahoo.com logoAcura Pharmaceutical Initiates Second Clinical Study on LTX-04
finance.yahoo.com - May 19 at 9:48 AM
americanbankingnews.com logoAcura Pharmaceuticals, Inc. (ACUR) Releases Quarterly Earnings Results, Beats Estimates By $0.14 EPS
www.americanbankingnews.com - May 15 at 11:30 AM
americanbankingnews.com logoAcura Pharmaceuticals (ACUR) Given Coverage Optimism Score of 0.07
www.americanbankingnews.com - May 2 at 9:25 AM
americanbankingnews.com logoAcura Pharmaceuticals (ACUR) Earning Somewhat Favorable Media Coverage, Study Shows
www.americanbankingnews.com - April 29 at 8:46 AM
americanbankingnews.com logoFavorable Press Coverage Somewhat Likely to Affect Acura Pharmaceuticals (ACUR) Stock Price
www.americanbankingnews.com - April 24 at 11:48 AM
americanbankingnews.com logoAcura Pharmaceuticals (ACUR) Earns Daily News Sentiment Score of -0.09
www.americanbankingnews.com - April 20 at 10:39 AM
americanbankingnews.com logoAcura Pharmaceuticals (ACUR) Receives Daily Coverage Optimism Score of 0.56
www.americanbankingnews.com - April 15 at 8:22 AM
finance.yahoo.com logoAcura Pharmaceuticals, Inc. :ACUR-US: Earnings Analysis: Q4, 2016 By the Numbers : April 4, 2017
finance.yahoo.com - April 7 at 6:01 AM
finance.yahoo.com logoETFs with exposure to Acura Pharmaceuticals, Inc. : April 5, 2017
finance.yahoo.com - April 7 at 6:01 AM
finance.yahoo.com logoEdited Transcript of ACUR earnings conference call or presentation 3-Apr-17 12:30pm GMT
finance.yahoo.com - April 4 at 1:30 AM
globenewswire.com logoAcura Pharmaceuticals Announces Fourth Quarter 2016 and Full Year 2016 Financial Results - GlobeNewswire (press release)
globenewswire.com - April 1 at 3:18 PM
finance.yahoo.com logoAcura Pharmaceuticals Announces Fourth Quarter 2016 and Full Year 2016 Financial Results
finance.yahoo.com - March 31 at 8:26 PM
biz.yahoo.com logoACURA PHARMACEUTICALS, INC Files SEC form 10-K, Annual Report
biz.yahoo.com - March 31 at 8:26 PM
biz.yahoo.com logoACURA PHARMACEUTICALS, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
biz.yahoo.com - March 31 at 8:26 PM
seekingalpha.com logoAcura Pharmaceuticals reports Q4 results
seekingalpha.com - March 31 at 4:25 PM
nasdaq.com logoAcura Pharmaceuticals and MainPointe Pharmaceuticals Announce Deal for Nexafed® Products - Nasdaq
www.nasdaq.com - March 17 at 3:41 PM
finance.yahoo.com logoAcura Pharmaceuticals and MainPointe Pharmaceuticals Announce Deal for Nexafed® Products
finance.yahoo.com - March 17 at 3:41 PM
finance.yahoo.com logo6:16 am Acura Pharma and MainPointe Pharmaceuticals announce that they have entered into a License Agreement to have MainPointe exclusively market NEXAFED and NEXAFED Sinus in the US and Canada; the agreement provided for an upfront cash pa
finance.yahoo.com - March 17 at 3:41 PM
biz.yahoo.com logoACURA PHARMACEUTICALS, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Finan
biz.yahoo.com - March 17 at 3:41 PM
nasdaq.com logoDelisting of Securities of Spanish Broadcasting System, Inc., Acura Pharmaceuticals, Inc., Vanguard Natural ... - Nasdaq
www.nasdaq.com - March 14 at 3:18 PM
globenewswire.com logoDelisting of Securities of Spanish Broadcasting System, Inc., Acura ... - GlobeNewswire (press release)
globenewswire.com - March 14 at 8:19 AM
finance.yahoo.com logoEssex Woodlands Health Ventures, Inc. Buys Acura Pharmaceuticals - Yahoo Finance
finance.yahoo.com - March 8 at 3:19 PM
finance.yahoo.com logoACURA PHARMACEUTICALS, INC Financials
finance.yahoo.com - February 28 at 3:22 PM
biz.yahoo.com logoACURA PHARMACEUTICALS, INC Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - February 24 at 8:17 PM
biz.yahoo.com logoACURA PHARMACEUTICALS, INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
biz.yahoo.com - February 22 at 8:21 PM
streetinsider.com logoAcura Pharma (ACUR) to Trade on OTC Markets After Failing to Comply with Nasdaq Listing Rule
www.streetinsider.com - February 16 at 8:22 PM
streetinsider.com logoAcura Pharma (ACUR) to Trade on OTC Markets After Failing to Comply with Nasdaq Listing Rule
www.streetinsider.com - February 16 at 8:22 PM
streetinsider.com logoAcura Pharma (ACUR) to Trade on OTC Markets After Failing to Comply with Nasdaq Listing Rule
www.streetinsider.com - February 16 at 8:22 PM
us.rd.yahoo.com logoAcura Pharmaceuticals Common Stock To Trade On The OTCQB Market
us.rd.yahoo.com - February 16 at 8:22 PM
us.rd.yahoo.com logoAcura Pharmaceuticals Common Stock To Trade On The OTCQB Market
us.rd.yahoo.com - February 16 at 8:22 PM
us.rd.yahoo.com logo4:18 pm Acura Pharma to be delisted from the Nasdaq; will begin to trade under the same ticker on the OTCQB on February 23
us.rd.yahoo.com - February 16 at 8:22 PM
benzinga.com logo22 Biggest Mid-Day Losers For Thursday - Benzinga
www.benzinga.com - February 16 at 3:21 PM
finance.yahoo.com logoAcura Pharmaceuticals Common Stock To Trade On The OTCQB Market - Yahoo Finance
finance.yahoo.com - February 16 at 6:32 AM

Social

Chart

Acura Pharmaceuticals (ACUR) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by MarketBeat.com Staff